Linear mixed effect model to show C-peptide/glucose progression over time in the intent-to-treat population. Shown is the best of tested linear mixed effect models selected according to the Akaike Information Criterion. The model predicts the progression of C-peptide/glucose over time while taking into account treatment arm, inter-subject variability and fixed effect due to seven additional covariates: C-peptide/glucose at baseline, fasting C-peptide at baseline, glycemia at baseline, HLA-DQ8 status, HLA-DR3/HLA-DQ2 status, HLA-DR4 status, and gender. Regression coefficients were analyzed via Mann-Whitney-Wilcoxon test. Central lines represent median values, boxes represent interquartile range, and whiskers represent upper and lower 1.5 x interquartile range. Shaded bands around the regression lines represent 95% confidence intervals on the fitted values. The ranges displayed in brackets are 95% confidence intervals, which were assessed by computing a likelihood profile and finding the appropriate cutoffs based on the likelihood ratio test. All plotted data are biological replicates. Dose A: 50 ug at week 0 followed by 3 x 25 ug; dose B: 150 ug at week 0 followed by 3 x 75 ug; dose C: 450 ug at week 0 followed by 3 x 225 ug
